title: Methylglyoxal modulates immune responses: relevance to diabetes.
abstract: Increased methylglyoxal (MG) concentrations and formation of advanced glycation end-products (AGEs) are major pathways of glycaemic damage in diabetes, leading to vascular and neuronal complications. Diabetes patients also suffer increased susceptibility to many common infections, the underlying causes of which remain elusive. We hypothesized that immune glycation damage may account for this increased susceptibility. We previously showed that the reaction mixture (RM) for MG glycation of peptide blocks up regulation of CD83 in myeloid cells and inhibits primary stimulation of T cells. Here, we continue to investigate immune glycation damage, assessing surface and intracellular cytokine protein expression by flow cytometry, T-cell proliferation using a carboxyfluorescein succinimidyl ester assay, and mRNA levels by RT-PCR. We show that the immunomodulatory component of this RM was MG itself, with MG alone causing equivalent block of CD83 and loss of primary stimulation. Block of CD83 expression could be reversed by MG scavenger N-acetyl cysteine. Further, MG within RM inhibited stimulated production of interleukin (IL)-10 protein from myeloid cells plus interferon (IFN)-gamma and tumour necrosis factor (TNF)-alpha from T cells. Loss of IL-10 and IFN-gamma was confirmed by RT-PCR analysis of mRNA, while TNF-alpha message was raised. Loss of TNF-alpha protein was also shown by ELISA of culture supernatants. In addition, MG reduced major histocompatibility complex (MHC) class I expression on the surface of myeloid cells and increased their propensity to apoptose. We conclude that MG is a potent suppressor of myeloid and T-cell immune function and may be a major player in diabetes-associated susceptibility to infection.
authors.affiliation: Antigen Presentation Research Group, Imperial College London, Northwick Park and St. Marks Campus, Harrow, Middlesex, UK.
authors.forename: Claire L
authors.initials: CL
authors.lastname: Price
authors.forename: Hafid O S Al
authors.initials: HO
authors.lastname: Hassi
authors.forename: Nicholas R
authors.initials: NR
authors.lastname: English
authors.forename: Alexandra I F
authors.initials: AI
authors.lastname: Blakemore
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Stagg
authors.forename: Stella C
authors.initials: SC
authors.lastname: Knight
mesh_terms: D015703:Antigens, CD / Q000378:metabolism; D017209:Apoptosis; D049109:Cell Proliferation; D016207:Cytokines / Q000096:biosynthesis / Q000235:genetics; D003920:Diabetes Mellitus / Q000276:immunology*; D005786:Gene Expression Regulation; D015395:Histocompatibility Antigens Class I / Q000378:metabolism; D006801:Humans; D007136:Immunoglobulins / Q000378:metabolism; D056747:Immunomodulation / Q000276:immunology*; D008562:Membrane Glycoproteins / Q000378:metabolism; D022423:Myeloid Cells / Q000166:cytology / Q000276:immunology; D011765:Pyruvaldehyde / Q000276:immunology*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology; D000097802:CD83 Antigen
chemical_list: D015703:Antigens, CD; D016207:Cytokines; D015395:Histocompatibility Antigens Class I; D007136:Immunoglobulins; D008562:Membrane Glycoproteins; D011765:Pyruvaldehyde; D012333:RNA, Messenger; D000097802:CD83 Antigen